Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells.
André T et al. Cancer Immunol Immunother. 2014 Oct 24. [Epub ahead of print].
Inhibition of Akt-signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.
van der Waart AB et al. Blood. 2014 Oct 21. pii: blood-2014-05-578583. [Epub ahead of print].
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma.
Zhang W et al. PLoS One. 2014 Oct 17;9(10):e110973. doi: 10.1371/journal.pone.0110973. eCollection 2014.
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Umezu T et al. Blood. 2014 Oct 15. pii: blood-2014-05-576116. [Epub ahead of print].
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors.
Tornatore L et al. Cancer Cell. 2014 Oct 13;26(4):495-508. doi: 10.1016/j.ccr.2014.07.027.
Numerous Russell bodies and Dutcher bodies in multiple myeloma.
van Gammeren AJ et al. Br J Haematol. 2014 Oct 14. doi: 10.1111/bjh.13181. [Epub ahead of print].
Immune cell inhibition by SLAMF7 is mediated by mechanism requiring Src kinases, CD45 and SHIP-1 defective in multiple myeloma cells.
Guo H et al. Mol Cell Biol. 2014 Oct 13. pii: MCB.01107-14. [Epub ahead of print].
Liposomal Carfilzomib Nanoparticles Effectively Target Multiple Myeloma Cells and Demonstrate Enhanced Efficacy In Vivo.
Ashley JD et al. J Control Release. 2014 Oct 10. pii: S0168-3659(14)00679-8. doi: 10.1016/j.jconrel.2014.10.005. [Epub ahead of print].
Differential regulation of FGFR3 by PTPN1 and PTPN2.
St-Germain JR et al. Proteomics. 2014 Oct 14. doi: 10.1002/pmic.201400259. [Epub ahead of print].
Adipocyte-derived players in hematologic tumors: useful novel targets?
Jöhrer K et al. Expert Opin Biol Ther. 2014 Oct 11:1-17. [Epub ahead of print].
Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R et al. Leukemia. 2014 Oct 13. doi: 10.1038/leu.2014.300. [Epub ahead of print].
Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in vitro and in xenograft models.
Zi FM et al. Cancer Lett. 2014 Oct 8. pii: S0304-3835(14)00591-6. doi: 10.1016/j.canlet.2014.09.050. [Epub ahead of print].
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3 P) in -17p high risk disease.
Kortüm KM et al. Br J Haematol. 2014 Oct 10. doi: 10.1111/bjh.13171. [Epub ahead of print].
Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.
Auner HW et al. Br J Haematol. 2014 Oct 9. doi: 10.1111/bjh.13172. [Epub ahead of print].
Role of osteocytes in multiple myeloma bone disease.
Delgado-Calle J et al. Curr Opin Support Palliat Care. 2014 Oct 6. [Epub ahead of print].
Diet-induced obesity promotes a myeloma-like condition in vivo.
Lwin ST et al. Leukemia. 2014 Oct 7. doi: 10.1038/leu.2014.295. [Epub ahead of print].
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B et al. Cancer Immunol Immunother. 2014 Oct 7. [Epub ahead of print].
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.
Sun C et al. PLoS One. 2014 Oct 6;9(10):e108839. doi: 10.1371/journal.pone.0108839. eCollection 2014.
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Ramakrishnan V et al. Leuk Res. 2014 Sep 28. pii: S0145-2126(14)00269-0. doi: 10.1016/j.leukres.2014.09.004. [Epub ahead of print].
Let-7b-5p regulates proliferation and apoptosis in multiple myeloma by targeting IGF1R.
Xu H et al. Acta Biochim Biophys Sin (Shanghai). 2014 Sep 30. pii: gmu089. [Epub ahead of print].
Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches.
Wong D et al. PLoS One. 2014 Oct 1;9(10):e109018. doi: 10.1371/journal.pone.0109018. eCollection 2014.
Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.
Crowely MP et al. J Thromb Thrombolysis. 2014 Oct 1. [Epub ahead of print].
Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
Chinen Y et al. Cancer Res. 2014 Sep 30. pii: canres.1420.2014. [Epub ahead of print].
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A et al. Oncotarget. 2014 Sep 30;5(18):8284-305.
c-Rel Regulates Ezh2 Expression in Activated Lymphocytes and Malignant Lymphoid Cells.
Neo WH et al. J Biol Chem. 2014 Sep 29. pii: jbc.M114.574517. [Epub ahead of print].